## 参考文献

> 以下参考文献按在报告正文中首次出现的顺序排列，编号与正文引用标注（[src_xxx]）一一对应。
> 格式参照 GB/T 7714-2015。Tier 标注说明：Tier 1 = 一级信源（学术/监管/年报原文）；Tier 2 = 二级信源（市场报告/行业媒体）；Tier 3/4 = 辅助参考。
> 标注 ⚠️ 的条目表示该信源未在 sources.jsonl 中留有完整记录，相关信息系根据正文上下文推断，建议人工核查。

⚠️ [src_001] Analysis of N-glycoprotein glycosylation patterns in approved FDA Biologics License Applications (BLAs) — establishing glycan benchmarks for lot-release. *PubMed/Journal*, 2026.
  *（Tier 1；journal；注：PubMed PMID 41577853；分析2025年5月前全部209项获批BLA的Fc N-糖谱数据集）*

⚠️ [src_002] EMA Biologics Q&A: Glycoprofile testing as specification parameter for antibodies with ADCC mechanism (updated December 2024). *EMA Official Publication*, 2024.
  *（Tier 1；regulatory；注：EMA Q&A 2024年12月更新版；确立糖谱测试为ADCC相关抗体的最可靠规格参数）*

⚠️ [src_003] Global Biopharmaceutical Pipeline and Market Size Report 2025 — Late-stage clinical candidates and revenue forecast to 2030. *Market Intelligence Report*, 2025.
  *（Tier 2；market_report；注：2025年全球600+后期生物药候选分子数据；全球生物制药收入2024年突破400亿美元，预计2030年超700亿美元）*

⚠️ [src_004] Glycomics Market Size, Share & Trends Analysis Report 2026–2031 — CAGR 13.63%. *Mordor Intelligence*, 2025. URL: https://www.mordorintelligence.com/industry-reports/glycomics-market
  *（Tier 2；market_report；注：Mordor Intelligence；全球糖组学市场2025年约21.3亿美元，预计2031年增至45.8亿美元）*

⚠️ [src_005] Glycobiology Market Analysis — Pharma/Biotech End-User Share. *Coherent Market Insights*, 2024.
  *（Tier 2；market_report；注：Coherent Market Insights；制药/生物技术公司贡献糖组学市场终端用户约49.5%）*

⚠️ [src_006] FDA Clinical Pharmacology Considerations for Antibody-Drug Conjugates — Guidance for Industry (March 2024). *US FDA Guidance Document*, 2024. URL: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/
  *（Tier 1；regulatory；注：FDA 2024年3月 ADC临床药理学指导原则；明确ADC糖基化全面表征要求）*

⚠️ [src_007] NMPA 抗体偶联药物药学研究评价技术指导原则（2023年）. *NMPA 国家药品监督管理局*, 2023.
  *（Tier 1；regulatory；注：NMPA；明确ADC药学研究须完成糖基化修饰（含O-连接糖基化）的全面表征）*

⚠️ [src_008] Comprehensive characterization of N- and O-glycosylation in bispecific antibodies — Identification of xylose-type O-glycans (PMID 41155653). *PubMed/Journal*, 2024.
  *（Tier 1；journal；注：PubMed PMID 41155653；BsAb系统O-糖基化表征，发现xylose修饰型特殊O-糖结构）*

⚠️ [src_009] Genovis SmartEnzymes Technical Documentation — OpeRATOR performance on high-density O-glycosylated substrates (Etanercept). *Genovis AB Technical Publication*, 2024. URL: https://www.genovis.com
  *（Tier 2；technical；注：Genovis技术文献；S. oralis来源经典O-糖苷酶对高O-糖密度底物（Etanercept）处理效率的对比）*

⚠️ [src_010] Comparative assessment of commercial O-glycosidase products: NEB P0733, Merck G1163, QA-Bio E-G001 — substrate limitation on sialylated Core 1. *Technical/Market Assessment*, 2023.
  *（Tier 2；technical；注：经典GH101 O-糖苷酶三款主要商业产品酶学特征对比；NEB P0733、Merck G1163、QA-Bio同源性确认）*

⚠️ [src_011] Genovis Blog: OpeRATOR launched at ASMS 2017 — FDA interest in the new O-glycan analysis tool. *Genovis AB Blog*, 2019. URL: https://www.genovis.com/blog/
  *（Tier 3；company；注：Genovis博客；OpeRATOR 2017年ASMS首发，FDA团队迅速关注）*

⚠️ [src_012] Structural basis of mammalian mucin processing by OgpA (OpeRATOR) from Akkermansia muciniphila (DOI: 10.1038/s41467-020-18696-y). *Nature Communications*, 2020. DOI: 10.1038/s41467-020-18696-y. URL: https://www.nature.com/articles/s41467-020-18696-y
  *（Tier 1；journal；注：OgpA/OpeRATOR高分辨率X射线晶体结构，Nature Communications 2020）*

⚠️ [src_013] IMPa application to mucin-domain glycoproteins — SFG Annual Conference 2022 abstract. *Society for Glycobiology (SFG) Annual Conference*, 2022.
  *（Tier 3；conference；注：NEB; 2022年SFG年会摘要展示IMPa对密集O-糖基化黏蛋白域蛋白分析的优越性）*

⚠️ [src_014] NEB Glycoproteomics Brochure (2023) — O-Glycoprotease (IMPa, P0761) listed alongside classic O-Glycosidase P0733. *New England Biolabs Technical Documentation*, 2023. URL: https://www.neb.com
  *（Tier 2；technical；注：NEB糖蛋白组学产品手册；IMPa与经典P0733并列，标注现已收录O-糖蛋白酶（IMPa））*

⚠️ [src_015] Dual functional POGases — no universal O-glycosidase active against di-sialylated Core 1 (DOI: 10.1038/s41467-025-57143-8). *Nature Communications*, 2025. DOI: 10.1038/s41467-025-57143-8. URL: https://www.nature.com/articles/s41467-025-57143-8
  *（Tier 1；journal；注：Nature Communications 2025；POGase宽谱酶仍对di-sialylated Core 1无效，技术空白依然存在）*

⚠️ [src_016] Genovis AB Year-End Report 2024 and 2025 — SmartEnzymes organic growth 14%/17% driven by ADC demand. *Genovis AB Investor Relations*, 2025. URL: https://investor.genovis.com
  *（Tier 1；annual_report；注：Genovis上市年报；核心酶业务2024年有机增长14%，2025年增长17%（货币调整23%））*

⚠️ [src_104] CAZY GH101 Family: Endo-α-N-acetylgalactosaminidase — Family Summary and Characterized Members. *CAZy Database (INRAE/UBC)*, 2025. URL: http://www.cazy.org/GH101.html
  *（Tier 1；database；注：CAZy数据库GH101家族条目；成员分布、结构特征汇总）*

⚠️ [src_105] E. faecalis EngEF (B5UB72) — UniProt Entry / NCBI GenBank Reference Sequence. *UniProt/NCBI*, 2025. URL: https://www.uniprot.org/uniprotkb/B5UB72
  *（Tier 1；database；注：UniProt B5UB72；EngEF序列公开记录，确认蛋白质一级结构进入公共领域）*

[src_101] Identification and Molecular Cloning of a Novel GH Family of Core 1 Type O-Glycan-Specific Endo-alpha-N-Acetylgalactosaminidase from Bifidobacterium longum. *Journal of Biological Chemistry*, 2005. DOI: 10.1074/jbc.M506874200. URL: https://pubmed.ncbi.nlm.nih.gov/16141207/
  *（Tier 1；journal；注：GH101家族创始文献，确认TIM-barrel结构和GH13同源性，保留型机制）*

[src_102] SpGH101 Crystal Structure (PDB 3ECQ, 2.9A) - Pluvinage/Willis et al.. *Journal of Biological Chemistry*, 2010. DOI: 10.1074/jbc.M110.121517. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC2953539/
  *（Tier 1；structural；注：SpGH101首个晶体结构，2.9Ang分辨率，PDB 3ECQ）*

[src_103] Novel endo-alpha-N-acetylgalactosaminidases with broader substrate specificity. *Glycobiology*, 2008. DOI: 10.1093/glycob/cwn069. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC2553423/
  *（Tier 1；journal；注：关键：NEB内部选型报告。EngEF kcat=51.17 s-1 for Core1，最高；Core3 100%；E.coli pET-21a验证）*

[src_106] BRENDA EC 3.2.1.97 - E. faecalis B5UB72 (EngEF). *BRENDA (TU Braunschweig)*, 2026. URL: https://www.brenda-enzymes.org/enzyme.php?ecno=3.2.1.97&UniProtAcc=B5UB72&Org...
  *（Tier 2；database；注：EngEF动力学参数独立验证来源，与Koutsioulis 2008交叉一致）*

[src_107] O-Glycosidase 324716 - Merck Sigma-Aldrich Product Page. *Merck/Sigma-Aldrich*, 2025. URL: https://www.sigmaaldrich.com/DE/en/product/mm/324716
  *（Tier 2；product_db；注：SpGH101 E.coli重组，比活>=10 units/mg，6项旁活性阴性，适合LC-MS）*

[src_108] Libios EngEF (E-OGLYEF) Technical Data Sheet, Lot 130201c. *Libios*, 2017. URL: https://libios.fr/imgfr/produit/fichier/1_e-oglyef-data.pdf
  *（Tier 2；technical；注：EngEF批次实测数据：MW 158800 Da，pI 5.2，比活3.0 U/mg，pH 7.5）*

[src_110] Discovery and Development of Promiscuous O-Glycan Hydrolases (Q868G SpGH101 mutant). *ACS Chemical Biology*, 2021. DOI: 10.1021/acschembio.1c00316. URL: https://pubs.acs.org/doi/10.1021/acschembio.1c00316
  *（Tier 1；journal；注：Wardman/Withers Q868G单点突变扩展底物谱，kcat/Km对sialyl T-antigen提升4.8倍）*

[src_109] NEB O-Glycosidase P0733 Product Page + NEB Glycoproteomics Technical Guide. *New England Biolabs*, 2025. URL: https://www.neb.com/en-us/products/p0733-o-glycosidase
  *（Tier 2；product_db；注：P0733 40M units/mL，GlycoBuffer 2，37°C，需Neuraminidase预处理）*

[src_111] Novel Enzymes for O-glycan Analysis - Genovis CASSS 2018 Poster. *CASSS/Genovis*, 2018. URL: https://www.genovis.com/wp-content/uploads/2018-CASSS-Novel-Enzymes-for-O-gly...
  *（Tier 2；conference；注：独立验证EngEF唾液酸依赖局限；S.oralis O-糖苷酶优于E.faecalis EngEF）*

[src_120] Using Glycosidases to Remove, Trim, or Modify Glycans on Therapeutic Proteins. *BioProcess International*, 2022. URL: https://www.bioprocessintl.com/cell-line-development/using-glycosidases-to-re...
  *（Tier 2；journal；注：综述指出无已知广谱O-糖苷酶可切所有O-糖链，两款商业酶底物局限性明确（反方证据））*

[src_112] Dual functional POGases from bacteria encompassing broader O-glycanase and adhesin activities. *Nature Communications*, 2025. DOI: 10.1038/s41467-025-57143-8. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC11861894/
  *（Tier 1；journal；注：POGase宽谱酶发现；EngCP天然G868仍无sialyl Core 1活性，是Q868G反方证据。EngEF Km Core1=15.3 uM）*

[src_113] SHuffle T7 Competent E. coli C3026 - NEB Product Page. *New England Biolabs*, 2025. URL: https://www.neb.com/en-us/products/c3026-shuffle-t7-competent-e-coli
  *（Tier 2；product_db；注：SHuffle T7：Δgor ΔtrxB胞质氧化，DsbC组成型表达，BSL-1，适合复杂蛋白表达）*

[src_114] E. coli Cytoplasmic Expression of Disulfide-Bonded Proteins: SHuffle vs CyDisCo Side-by-Side Comparison. *IJMS (MDPI)*, 2024. DOI: 10.3390/ijms25115836. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC11180911/
  *（Tier 1；journal；注：SHuffle在T7富培养基下产量5-450 mg/L；CyDisCo在9/10蛋白更高产量（反方证据））*

[src_115] NEB Endo S2 P0761 QC Specifications - 类比参照. *New England Biolabs*, 2025. URL: https://www.neb.com/en-us/products/p0761-endo-s2
  *（Tier 2；product_db；注：[类比] QC复杂度估算参照，非P0733直接QC规格单）*

[src_116] PHAC PSDS: Enterococcus faecalis and Enterococcus faecium. *Public Health Agency of Canada*, 2023. URL: https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecur...
  *（Tier 1；regulatory；注：官方PSDS，E. faecalis Risk Group 2，Containment Level 2要求）*

[src_117] Samuel Merritt University Biosafety Manual Ver 2.0. *Samuel Merritt University EHS*, 2021. URL: https://www.samuelmerritt.edu/sites/default/files/2021-07/Biosafety%20Manual%...
  *（Tier 2；regulatory；注：明确E. faecalis需BSL-2实验室）*

[src_118] E. faecalis & E. faecium Agent Safety Guide - USC EHS. *USC EHS*, 2023. URL: https://sc.edu/about/offices_and_divisions/ehs/research_and_laboratory_safety...
  *（Tier 2；regulatory；注：BSL-2实验室要求，E.coli表达路径可绕开BSL-2）*

[src_119] GenScript BacPower E. coli Platform / Bestzyme CDMO Capability. *GenScript/Bestzyme*, 2025. URL: https://www.genscript.com/protein-expression-services.html
  *（Tier 2；company；注：[待验证] 金斯瑞BacPower 15g/L E.coli，2000L发酵规模；百斯杰2023年融资2.5亿RMB）*

[src_201] Koutsioulis D, Landry D, Guthrie EP. Novel endo-alpha-N-acetylgalactosaminidases with broader substrate specificity. *Glycobiology*, 2008. DOI: 10.1093/glycob/cwn069. URL: https://pubmed.ncbi.nlm.nih.gov/18635885/
  *（Tier 1；journal；注：EngEF (E. faecalis) 序列进入公共领域的核心文献，先公开奠定 FTO 基础；作者为 NEB 雇员但已在学术期刊公开发表）*

[src_202] Goda HM, Ushigusa K, Ito H 等. Molecular cloning, expression, and characterization of a novel endo-alpha-N-acetylgalactosaminidase from Enterococcus faecalis. *Biochem Biophys Res Commun*, 2008. DOI: 10.1016/j.bbrc.2008.08.065. URL: https://www.sciencedirect.com/science/article/abs/pii/S0006291X08015714
  *（Tier 1；journal；注：日本团队独立克隆 E. faecalis GH101，与 Koutsioulis 2008 同年独立发表，相互印证 EngEF 序列公共领域地位）*

[src_203] US Congress. America Invents Act (AIA), Pub.L. 112-29, 35 U.S.C.. *US Federal Law*, 2011. URL: https://www.uspto.gov/sites/default/files/aia_implementation/20110916-pub-l11...
  *（Tier 1；regulatory；注：美国专利法 AIA 先申请制与现有技术规则，第三方公开不享有宽限期豁免）*

[src_204] Caines ME, Zhu H, Vuckovic M 等. The structural basis for T-antigen hydrolysis by Streptococcus pneumoniae: a target for structure-based vaccine design. *J Biol Chem*, 2008. DOI: 10.1074/jbc.C800150200. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC4646209/
  *（Tier 1；journal；注：SpGH101 首个晶体结构（2.9 Å），明确为学术公开，确立 SpGH101 结构进入公共领域）*

[src_205] Willis LM, Zhang R, Reid A 等. Mechanistic investigation of the endo-alpha-N-acetylgalactosaminidase from Streptococcus pneumoniae R6. *Biochemistry*, 2009. DOI: 10.1021/bi9013825. URL: https://www.chem.ubc.ca/mechanistic-investigation-endo-alpha-n-acetylgalactos...
  *（Tier 1；journal；注：确认 SpGH101 催化残基 D764（亲核）和 E796（广义酸碱），机制研究进入公共领域）*

[src_206] Magnelli P, Guthrie E, Taron CH 等. EP3149034B1 - Deglycosylation reagents and methods. 2022. URL: https://patents.google.com/patent/EP3149034B1/en
  *（Tier 1；patent；注：NEB 核心脱糖基化专利；独立权利要求聚焦 N-糖苷酶+非 SDS 表面活性剂体系；O-糖苷酶仅在从属权利要求中出现。预计 2035 年到期，中国同族专利状态需 CNIPA 独立核查）*

[src_207] Trastoy B, Naegeli A, Anso I 等. Structural basis of mammalian mucin processing by the human gut O-glycopeptidase OgpA from Akkermansia muciniphila. *Nat Commun*, 2020. DOI: 10.1038/s41467-020-18707-y. URL: https://www.genovis.com/blog/the-ctrystal-structure-of-operator-reveals-o-gly...
  *（Tier 1；journal；注：OpeRATOR 晶体结构公开，是下一代酶结构进入公共领域的里程碑；但 Genovis 商业化工艺可能仍受保护）*

[src_208] Tender GS, Bertozzi CR, et al. Design of a mucin-selective protease for targeted degradation of cancer-associated mucins. *Nat Biotechnol*, 2023. DOI: 10.1038/s41587-023-01840-6. URL: https://www.nature.com/articles/s41587-023-01840-6
  *（Tier 1；journal；注：eStcE 为黏蛋白选择性蛋白酶（切肽键），与本项目 O-糖苷酶（切糖苷键）属不同酶类，不构成直接 FTO 障碍）*

[src_209] Wardman JF, Sim L, Liu J 等. A high-throughput screening platform for enzymes active on mucin-type O-glycoproteins. *Nat Methods*, 2023. DOI: 10.1038/s41592-023-01961-7. URL: https://pubmed.ncbi.nlm.nih.gov/37592157/
  *（Tier 1；journal；注：Withers/UBC 高通量 O-糖肽酶筛选平台（FRET 探针+液滴微流控），已申请 UBC 专利；方法受保护，但筛选所得新酶序列不受此专利覆盖）*

[src_210] Wardman JF, Rahfeld P, Liu F 等. Discovery and Development of Promiscuous O-Glycan Hydrolases for Removal of Intact Sialyl T-Antigen. *ACS Chem Biol*, 2021. DOI: 10.1021/acschembio.1c00316. URL: https://pubmed.ncbi.nlm.nih.gov/34309358/
  *（Tier 1；journal；注：SpGH101 Q868G 突变体首次公开报道，可切除完整唾液酸 T-抗原；宏基因组筛选发现 GH101 家族隐性 STAg 水解活性）*

[src_211] Wardman, Jacob Franklin. Discovery and engineering of enzymes for the manipulation of glycoproteins (PhD Thesis). 2023. URL: https://open.library.ubc.ca/soa/cIRcle/collections/ubctheses/24/items/1.0438625
  *（Tier 2；thesis；注：系统描述 STAg 水解酶发现、超高通量液滴筛选平台及最优突变体（140倍活性提升））*

[src_212] See Nature Communications 2025 author list. Dual functional POGases from bacteria encompassing broader O-glycanase and adhesin activities. *Nat Commun*, 2025. DOI: 10.1038/s41467-025-57143-8. URL: https://www.nature.com/articles/s41467-025-57143-8
  *（Tier 1；journal；注：2025 年最新 GH101 研究，POGase 宽谱酶（sialyl Core 1/2/3）；Kcat/Km 比 EngEF 高 >300 倍；Motif-1/2/3 三段特征序列与已知酶不同，为新...）*

[src_213] Withers SG group. Reshaping of a Glycoside Hydrolase Active Site through Expression in Vivo Directed Evolution. *ACS Cent Sci*, 2024. DOI: 10.1021/acscentsci.5c01227. URL: https://pubs.acs.org/doi/10.1021/acscentsci.5c01227
  *（Tier 1；journal；注：SpGH101 Q868G 定向进化后活性提升 140 倍，证明 Withers/UBC 正在积极推进该方向专利布局，新进者需选择 EngEF 同源位点或全新骨架）*

[src_301] Sivashanmugam A, Murray V, Cui C 等. Optimizing recombinant protein expression via automated induction profiling in microtiter plates at different temperatures. *BMC Biotechnology (approx.)/PMC5706349*, 2017. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC5706349/
  *（Tier 2；journal；注：系统评估不同温度下IPTG浓度优化：最优IPTG为0.05–0.1 mM；高温时最优IPTG更低；支持低浓度IPTG用于改善可溶性）*

[src_302] San-Miguel T, Pérez-Bermejo P, Gavilanes F. Production of soluble eukaryotic recombinant proteins in E. coli is favoured in early log-phase cultures induced at low temperature. *SpringerPlus*, 2013. DOI: 10.1186/2193-1801-2-89. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3602615/
  *（Tier 1；journal；注：系统证明低温（16–23°C）诱导显著改善>80 kDa蛋白可溶性；早期对数期+低温组合最优；支持EngEF低温诱导策略）*

[src_303] Lobstein J, Emrich CA, Jeans C 等. SHuffle, a novel Escherichia coli protein expression strain capable of correctly folding disulfide bonded proteins in its cytoplasm. *Microbial Cell Factories*, 2012. DOI: 10.1186/1475-2859-11-56. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3526497/
  *（Tier 1；journal；注：SHuffle T7菌株原始描述论文：Δgor ΔtrxB氧化胞质+染色体DsbC；T7富培养基下5–450 mg/L产量区间；适合多二硫键蛋白）*

[src_304] Fox JD, Waugh DS. The Ability to Enhance the Solubility of Its Fusion Partners Is an Intrinsic Property of Maltose-Binding Protein but Their Folding Is Either Spontaneous or Chaperone-Mediated. *PLOS ONE*, 2012. DOI: 10.1371/journal.pone.0049589. URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0049589
  *（Tier 1；journal；注：MBP溶解性增强机制（holdase）的系统研究；MBP融合将多种蛋白可溶性从<5%提升至30–60%；与NusA对比；作为标准溶解性标签被广泛引用）*

[src_306] Costa SJ, Almeida A, Castro A 等. Fusion tags for protein solubility, purification and immunogenicity in Escherichia coli: the novel Fh8 system. *Frontiers in Microbiology*, 2014. DOI: 10.3389/fmicb.2014.00063. URL: https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2014...
  *（Tier 2；journal；注：MBP（43 kDa）和SUMO（~12 kDa）融合标签综述；TEV蛋白酶切除方案；SUMO适合N端敏感应用；支持MBP/SUMO策略选择依据）*

[src_307] PMC12341298 author list. Engineering Bacillus subtilis for high-value bioproduction: recent advances and applications. *Microbial Cell Factories (PMC12341298)*, 2025. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC12341298/
  *（Tier 1；journal；注：B. subtilis占全球工业酶市场~60%；GRAS地位；天然分泌能力优势；WB600菌株分泌天冬酰胺酶407.6 U/mL；对比E. coli的包涵体劣势）*

[src_308] van Dijl JM, Hecker M. Recombinant protein secretion by Bacillus subtilis and Lactococcus lactis: pathways, applications, and innovation potential. *Applied Microbiology and Biotechnology (PMC8314018)*, 2021. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8314018/
  *（Tier 2；journal；注：欧洲工业酶年营业额>20亿欧元；洗涤剂蛋白酶年产900吨纯酶；B. subtilis分泌能力综述；Sec通路详细机制）*

[src_309] FDA. Bacillus subtilis NRRL 68054 GRAS Notice - FDA GRN Database. *US FDA GRAS Notice Inventory*, 2025. URL: https://downloads.regulations.gov/FDA-2025-N-1927-0061/attachment_1.pdf
  *（Tier 1；regulatory；注：FDA GRN库中有25条B. subtilis相关GRAS通知，20条已获no-questions回函；证明B. subtilis GRAS地位的一级监管文件）*

[src_310] Krishnappa L et al.. Bottleneck in secretion of alpha-amylase in Bacillus subtilis. *Microbial Cell Factories*, 2017. DOI: 10.1186/s12934-017-0739-5. URL: https://pubmed.ncbi.nlm.nih.gov/28724440/
  *（Tier 1；journal；注：B. subtilis Sec通路分泌>80 kDa大蛋白存在瓶颈（反方证据）；α-淀粉酶案例；提示EngEF（108 kDa）迁移B. subtilis需截短体策略）*

[src_311] Ahmad M et al.. Pichia pastoris: A highly successful expression system for optimal synthesis of foreign proteins. *Molecular Biotechnology (PMC7228273)*, 2014. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC7228273/
  *（Tier 1；journal；注：Pichia OCH1控制超糖基化；O-甘露糖化对酶活性的干扰综述；GlycoSwitch技术局限（主要针对N-糖，O-甘露糖化方案不完善）；支持否决Pichia用于O-糖苷酶的关键综述）*

[src_313] Jacobs PP et al.. Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology. *Nature Protocols*, 2009. DOI: 10.1038/nprot.2008.213. URL: https://pubmed.ncbi.nlm.nih.gov/19131957/
  *（Tier 1；journal；注：GlycoSwitch技术：OCH1敲除+异源糖基转移酶改造Pichia N-糖基化；每步工程约需3周；注意该技术主要针对N-糖，O-甘露糖化问题未解决（反方/限制证据））*

[src_314] US CDC. CDC Quick Learn: Recognize the four Biosafety Levels. *US Centers for Disease Control and Prevention*, 2024. URL: https://www.cdc.gov/training/quicklearns/biosafety/
  *（Tier 1；regulatory；注：BSL-2要求：BSC操作+门禁+高压灭菌废物+工作人员培训。E. coli K-12衍生株（BL21/SHuffle）为BSL-1，全程兼容普通CDMO。来源CDC官方培训材料）*

[src_401] Mordor Intelligence. Glycomics Market Size, Share, Growth & Trends Report 2030 — Drug Discovery Segment. *Mordor Intelligence*, 2025. URL: https://www.mordorintelligence.com/industry-reports/glycomics-market
  *（Tier 2；market_report；注：制药/生物技术公司2025年贡献48.62%的糖组学市场营收；ADC应用是关键增长驱动）*

[src_402] Coherent Market Insights. Glycobiology Market — Enzyme & Product Analysis (Coherent Market Insights). *Coherent Market Insights*, 2024. URL: https://www.coherentmarketinsights.com/market-insight/glycobiology-market-3639
  *（Tier 2；market_report；注：酶类产品占糖生物学产品价值约40-55%，是最大品类）*

[src_403] Grand View Research. U.S. Glycomics Market Size & Share | Industry Report, 2030 (Grand View Research). *Grand View Research*, 2024. URL: https://www.grandviewresearch.com/industry-analysis/us-glycomics-market-report
  *（Tier 2；market_report；注：学术与科研机构2023年占糖组学终端用户约39%，居最高；药物发现占最大应用份额）*

[src_404] 翌圣生物科技（上海）股份有限公司. 翌圣生物科技（上海）股份有限公司招股说明书（科创板上会稿，含Frost & Sullivan中国生物试剂市场数据）. *上海证券交易所科创板*, 2023. URL: http://static.sse.com.cn/stock/disclosure/announcement/c/202306/001182_202306...
  *（Tier 1；ipo_prospectus；注：2021年中国生物试剂科研市场规模183亿元；进口品牌占科研机构用户市场约90%；是中国生物试剂市场最权威的一手披露来源之一）*

[src_405] ICH, EMA. ICH Q2(R2) Guideline on Validation of Analytical Procedures — Step 5 (EMA effective June 2024). *EMA Official Publication*, 2024. URL: https://www.ema.europa.eu/en/ich-q2r2-validation-analytical-procedures-scient...
  *（Tier 1；regulatory_guideline；注：ICH Q2(R2) 2023年修订版，EMA 2024年6月生效；引入分析生命周期管理框架；CMC方法验证的最高权威指引）*

[src_406] Zhang et al.; CNKI综述. IgA Nephropathy in China: Epidemiology, Clinical Features and Disease Burden (多篇系统综述合并引用). *PubMed / CNKI 综合*, 2022. URL: https://pubmed.ncbi.nlm.nih.gov/?term=IgA+nephropathy+China+prevalence+epidem...
  *（Tier 2；review_meta；注：[待验证] 500万例数字见于多篇meta分析，建议回溯CNKI原始流行病学调查文献校正）*

[src_407] 药明合联（WuXi XDC）, 港交所. WuXi XDC Cayman Inc. Annual Report 2024. *港交所上市公司年报（2268.HK）*, 2025. URL: https://www.hkexnews.hk/listedco/listconews/sehk/2025/0429/2025042903387.pdf
  *（Tier 1；annual_report；注：截至2024年12月31日194个正在进行的iCMC整合项目；分析表征使用HPLC/ELISA/LC-MS测量包括糖基化在内的关键参数）*

[src_408] Chris Liu, Invesco Asset Management. How are ADC drug partnerships changing China's biotech landscape? (Invesco, October 2024). *Invesco APAC Insights*, 2024. URL: https://www.invesco.com/content/dam/invesco/apac/en/pdf/insights/2024/october...
  *（Tier 2；investment_report；注：中国ADC对外授权交易2022-2024年35笔，超过美国25笔，是全球最大授权国；截至2024年全球230+款ADC在临床）*

[src_409] 华创证券研究所. 华创证券·医药投资观点周周谈第70期：造影剂市场国产替代东风已至（含生命科学服务进口替代板块）. *华创证券*, 2024. URL: https://aigc.idigital.com.cn（华创证券研报平台）
  *（Tier 3；equity_research；注：仅作辅助引用；核心数据引自公开招股书；生物科研试剂2021年国产份额约10%（科研端））*

[src_410] US FDA. Analytical Procedures and Methods Validation for Drugs and Biologics — FDA Guidance for Industry. *FDA Guidance Document（现行有效）*, 2015. URL: https://www.fda.gov/files/drugs/published/Analytical-Procedures-and-Methods-V...
  *（Tier 1；regulatory_guideline；注：FDA现行有效指引；试剂替换触发再验证或等效性研究；商业化阶段变更需PAS并等待监管审批）*

[src_411] BioPhorum. Best practices for the development, validation and registration of analytical procedures — Implementation of ICH Q2(R2) and Q14 for biologics (BioPhorum). *BioPhorum (Pharma industry consortium)*, 2025. URL: https://www.biophorum.com/download/best-practices-for-the-development-validat...
  *（Tier 2；industry_guidance；注：BioPhorum是制药行业联盟（无商业利益冲突）；ICH Q2(R2)+Q14联合实施最佳实践；分析程序档案（APD）中供应商信息一旦注册即形成变更控制壁垒）*

[src_412] Genovis AB. Genovis AB Interim Report January–September 2024. *Genovis AB (Nasdaq First North Growth Market)*, 2024. URL: https://investor.genovis.com/en/mfn_news/interim-report-january-september-2024/
  *（Tier 1；interim_report；注：2024年Q3酶类（analytics）销售额SEK 3,160万，同比增长24%，创单季历史新高；增长主要来自ADC技术相关大单；证明ADC驱动的糖分析酶市场实质性扩张）*

⚠️ [src_501] NEB O-Glycosidase P0733 Pricing — North America List Price and Academic Contract (TCEFS 2025). *New England Biolabs*, 2025. URL: https://www.neb.com/en-us/products/p0733-o-glycosidase
  *（Tier 2；product_catalog；注：NEB P0733官方定价；P0733S$137 / P0733L$525（TCEFS 2025协议价））*

[src_502] Merck Sigma-Aldrich / Scientific Laboratory Supplies. O-Glycosidase from Streptococcus pneumoniae G1163 — Merck Sigma-Aldrich via SLS UK. *scientificlabs.com (Merck authorized UK distributor)*, 2025. URL: https://www.scientificlabs.com/en/product/protein-assays/g1163-.04un
  *（Tier 2；product_catalog；注：英国区报价；美国区 Sigma-Aldrich G1163 定价需登录后查看，无法获取，本信源仅作欧洲市场参照）*

[src_503] Bio-Techne Corporation, StockAnalysis.com (Fiscal.ai data aggregator). Bio-Techne Corporation (TECH) Income Statement FY2021-FY2025 — SEC 10-K Data. *SEC 10-K / StockAnalysis*, 2025. URL: https://stockanalysis.com/stocks/tech/financials/
  *（Tier 1；financial；注：Bio-Techne 作为生命科学试剂行业上市公司参照；NEB 毛利率类比估算基准；FY 截止 6 月 30 日）*

[src_504] dr-analyst. 重组酶 E.coli 表达体系通用成本结构假设（内部推算）. *本研究内部逻辑推导*, 2026.
  *（Tier 3；internal_estimate；注：仅作估算支撑，不作为结论唯一来源）*

[src_505] 国元证券研究所, 东北证券. 打破生物试剂进口垄断，国产细分龙头崛起（诺唯赞/翌圣生物深度研报）. *Wind/东方财富研报平台*, 2023. URL: https://pdf.dfcfw.com/pdf/H3_AP202107151503924611_1.pdf
  *（Tier 2；equity_research；注：数据主要针对分子酶品类（PCR 酶、逆转录酶），与 O-糖苷酶品类存在差异，外推需谨慎）*

[src_506] L.E.K. Consulting. China's Life Sciences Sector in Transition: How Suppliers Can Thrive in the Next Chapter. *L.E.K. Consulting Insights*, 2024. URL: https://www.lek.com/insights/hea/cn/ei/chinas-life-sciences-sector-transition...
  *（Tier 2；consulting_report；注：L.E.K. 是 Tier 2 咨询机构，2024 年报告，时效性高，作为反方证据使用）*

[src_507] Genovis AB. Genovis OpeRATOR Lyophilized Product Page + Year-End Report January-December 2025. *Genovis Official Website / Genovis Investor Relations*, 2025. URL: https://www.genovis.com/product-group/operator/
  *（Tier 1；product_catalog_and_annual_report；注：OpeRATOR 价格 2026-04-20 查询确认；Genovis 年收入约 SEK 1.29 亿（~€1,110 万），中型酶企业）*

[src_508] New England Biolabs. O-Glycoprotease (IMPa) P0761S — NEB Product Page. *NEB Official Website*, 2026. URL: https://www.neb.com/en-us/products/p0761-o-glycoprotease
  *（Tier 1；product_catalog；注：IMPa 为 NEB 旗下下一代 O-糖蛋白酶，与 Genovis OpeRATOR 构成工程酶市场双寡头；具体售价未获取，需进一步查询）*

[src_413] New England Biolabs, UMass Medical School TCEFS Contract. New England Biolabs TCEFS 2025 Pricing List (effective 2025-01-29). *UMass Medical School Enzyme Freezer / NEB*, 2025. URL: https://www.umassmed.edu/globalassets/enzyme-freezer/documents/neb-tcefs-2025...
  *（Tier 2；price_list；注：NEB TCEFS 2025协议价格表：P0733S $137, P0733L $525, E0540S $190（O-糖苷酶+神经氨酸酶捆绑），P0720S神经氨酸酶$87。这是 NEB O-糖苷酶...）*

[src_414] BIOKÉ (NEB Authorized Distributor). O-Glycosidase & α2-3,6,8 Neuraminidase Bundle E0540S — BIOKÉ NL Product Page. *BIOKÉ B.V. (Netherlands)*, 2026. URL: https://www.bioke.com/webshop/neb/e0540.html
  *（Tier 2；distributor_catalog；注：NEB E0540S欧洲分销价€242；产品组成验证：双酶（O-糖苷酶+神经氨酸酶）+三种缓冲液组件；注：分销商价格非NEB官网直销价，仅作参照）*

[src_415] Genovis AB. Genovis SmartEnzymes Store — Complete Product Lineup with Official Pricing 2026. *Genovis AB Official Store*, 2026. URL: https://www.genovis.com/store/
  *（Tier 1；product_catalog；注：OglyZOR（O-糖苷酶，SpGH101来源）€1,079/2000u；OmniGLYZOR（N+O糖全套工作流套装）€1,524-2,739；SialEXO€781；为竞品工作流套装定价的核心参照...）*

[src_416] GenScript Corporation. GenScript BacPower™ E. coli Protein Expression Service — Technical Handbook & Service Brochure. *GenScript Official Technical Documentation*, 2022. URL: https://www.genscript.com/gsfiles/techfiles/B_Recombinant_Protein_Service_Han...
  *（Tier 2；technical_brochure；注：金斯瑞 BacPower™ 技术手册，明确支持 E. coli 1L-2000L 发酵规模，最大 3 吨湿菌体，克级蛋白纯度 ≥98%；具备包涵体复性平台 FoldArt™；是第 8 章 CDMO 能...）*

[src_417] 金斯瑞生物科技股份有限公司（HK:1548）. 合成生物学业务被市场看好 金斯瑞旗下百斯杰获2.5亿元融资. *金斯瑞官方新闻稿*, 2023. URL: https://www.genscript.com.cn/genscript-subsidiary-bestzyme-secured-rmb-250-mi...
  *（Tier 2；corporate_announcement；注：百斯杰 2023 A 轮融资 2.5 亿 RMB，高瓴领投 1 亿，投后估值约 24 亿 RMB；金斯瑞间接持股 82.5917%；百斯杰已开发 20+ 自主知识产权工业酶，全国酶制剂十强企业。）*

[src_418] 南京诺唯赞生物科技股份有限公司. 南京诺唯赞生物科技股份有限公司 2025 年半年度报告. *上交所科创板（688105.SH）*, 2025. URL: https://qxb-pdf-osscache.qixin.com/AnBaseinfo/14557464fc8814f446ef6129d742add...
  *（Tier 1；semi_annual_report；注：诺唯赞龙潭 GMP 车间已运行 GMP 级 10L-100L 发酵线；年产能满足 250 kg mRNA 生产；质量体系参照 GMP/ICH Q7/Q10/ISO 9001；2025H1 通过 SGS...）*

⚠️ [src_419] GenScript / Bestzyme Industrial Enzyme CDMO Capability — Fermentation Scale and Enzyme-Specific Capacity. *GenScript / Bestzyme Corporate Documentation*, 2024.
  *（Tier 2；company；注：金斯瑞/百斯杰工业酶CDMO能力概述；相关CDMO能力参考）*

[src_420] 东吴证券研究所. 细胞基因治疗CDMO行业深度报告（含CRB 2020行业调查数据，CDMO选择原因分布）. *中国医药工业信息中心/东吴证券*, 2021. URL: http://www.cnpharm.com/upload/resources/file/2021/08/04/96042.pdf
  *（Tier 3；equity_research；注：CRB 2020 调查：54% 企业选 CDMO 首因是'有限 GMP 能力'；CDMO 代工费占收入 15–25% 为行业均值；仅为估算参考，非 O-糖苷酶研究试剂级具体报价。[待验证：需获取专项报...）*

[src_421] 美泰诺格工程咨询. 生物安全实验室建设每平方米造价参考 + ISO 13485认证费用行业参考（美泰诺格实验室工程公司）. *美泰诺格公司官网*, 2023. URL: http://www.mtngjh.com/news/detail/831.html
  *（Tier 4；engineering_reference；注：Tier 4，仅用于量级参考；GMP 建设成本决策时建议向至少 3 家专业工程公司获取正式报价校正。）*

[src_422] 中国科学院上海有机化学研究所, 中国科学院过程工程研究所. 中科院上海有机所高级人才招聘启事（糖化学生物学）+ 中科院过程工程研究所糖生物工程课题组招聘. *中科院官网*, 2023. URL: https://sioc.cas.cn/team/zp/zxzp/202307/t20230719_6812596.html
  *（Tier 2；institutional_recruitment；注：SIOC 和过程工程所的糖生物学/糖化学人才招聘公告证明该方向人才主要向学术机构聚集；企业需提供 2–3 倍薪酬溢价才能竞争到此类人才。）*

[src_423] 中国科学院天津工业生物技术研究所. 中国科学院天津工业生物技术研究所2026年招聘启事（糖生物学/酶工程方向博士后）. *优秀人才网（中科院天津工业所授权发布）*, 2026. URL: https://www.youxiuhr.com/index.php?c=ads&id=222
  *（Tier 2；institutional_recruitment；注：天津工业所朱之光课题组招募糖生物学/酶工程博士后（2026年）；特别博士后年薪约 34 万税前（含公积金）+ 天津生活补贴 15 万/年；企业糖生物学 PI 需提供 2–3 倍溢价（80–120 万+...）*

[src_424] BOSS直聘, LinkedIn. 生物医药行业薪酬参考数据（BOSS直聘/领英公开招聘 2024–2026）. *公开招聘平台*, 2025. URL: https://www.zhipin.com
  *（Tier 4；job_posting_aggregate；注：Tier 4，基于公开招聘页面薪酬区间汇总，仅作首年团队薪酬总包量级估算；PI 薪酬区间弹性大，实际取决于候选人背景和谈判。）*

[src_425] Garg R, et al.. Challenges Associated With the Formation of Recombinant Protein Inclusion Bodies in Escherichia coli and Strategies to Address Them for Industrial Applications. *Frontiers in Microbiology (PMC7902521)*, 2021. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC7902521/
  *（Tier 2；review；注：E.coli过表达>80 kDa蛋白时包涵体发生率综合综述；是ch09 T1技术风险评分（概率4/5）的文献支撑；2021年综述，时效性可接受）*

[src_427] NMPA China. Provisions for In-Vitro Diagnostic Reagent Registration and Filing (NMPA Order No.48, 2021) — English version. *NMPA Official English Portal*, 2021. URL: https://english.nmpa.gov.cn/2024-06/05/c_1049322.htm
  *（Tier 1；regulatory；注：NMPA 2021年第48号令最新有效文本；IVD Class I仅需备案；RUO产品豁免注册是O-糖苷酶科研试剂18个月路径的关键合规依据；英文版本核查补充：中文版见国家药监局官网，英文版2024-...）*

[src_426] Szarka A, et al.. Enhanced Recombinant Protein Production of Soluble, Highly Active and Immobilizable PNGase F. *Biomolecules (PMC9259526)*, 2022. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC9259526/
  *（Tier 1；journal；注：PNGase F重组表达优化案例；作为GH101开发时间表和活性验证周期的类比参照；2022年Biomolecules（MDPI，IF约4.0）。注：PNGase F（37 kDa）远小于EngEF（...）*

[src_428] Abbott J, BioProcess International. CDMO selection: Startups need patience, humility, and good faith. *BioProcess International*, 2024. URL: https://www.bioprocessintl.com/deal-making/cdmo-selection-startups-need-patie...
  *（Tier 2；industry_article；注：BPI行业媒体文章，BPI Europe 2024会议报道；支持双CDMO布局策略和T3批间一致性风险评分逻辑）*

[src_429] Labiotech editorial team. 5 Reasons Why Biotech Startups Fail: How to Avoid Them. *Labiotech.eu*, 2023. URL: https://www.labiotech.eu/members/biotech-startups-failure-advice/
  *（Tier 3；industry_article；注：Tier3行业媒体；仅用于支持Kill Criteria设置的管理逻辑合理性，不作为核心技术结论唯一支撑）*

[src_430] Trastoy B, Naegeli A, Anso I 等. Structural basis of mammalian mucin processing by the human gut O-glycopeptidase OgpA from Akkermansia muciniphila. *Nature Communications*, 2020. DOI: 10.1038/s41467-020-18696-y. URL: https://www.nature.com/articles/s41467-020-18696-y
  *（Tier 1；journal；注：OpeRATOR结构解析奠基论文；2020年Nat Commun IF~17，102次引用；Trastoy/Guerin为学术作者，结构数据独立；利益冲突已声明，评分降0.5分；是OpeRATOR商品...）*

[src_431] Genovis AB. Genovis OpeRATOR Lyophilized / ImpaRATOR Lyophilized — Product Pages and Annual Report 2024. *Genovis official website + MFN Annual Report 2024*, 2024. URL: https://www.genovis.com/smartenzymes/glycan-profiling/operator/
  *（Tier 2；commercial；注：Genovis官网产品页（2025年检索）及2024年年报；产品参数直接来自商业页面，是定价和规格的第一手数据；需注意商业利益因素，但技术规格无动机虚报）*

[src_432] Chongsaritsinsuk J, Steigmeyer AD, Mahoney KE 等. Glycoproteomic landscape and structural dynamics of TIM family immune checkpoints enabled by mucinase SmE. *Nature Communications*, 2023. DOI: 10.1038/s41467-023-41756-y. URL: https://www.nature.com/articles/s41467-023-41756-y
  *（Tier 1；journal；注：SmE定义性论文；首次完成TIM家族完整O-糖组学图谱；提供OgpA/IMPa/SmE三款酶的直接基准测试数据；2023年Nat Commun，是迄今O-糖肽酶领域覆盖面最广的比较研究）*

[src_433] Vainauskas S, Duke RM, McFarland M 等. A Broad-Specificity O-Glycoprotease That Enables Improved Analysis of Glycoproteins and Glycopeptides Containing Intact Complex O-Glycans. *Analytical Chemistry*, 2022. DOI: 10.1021/acs.analchem.1c04055. URL: https://pubs.acs.org/doi/10.1021/acs.analchem.1c04055
  *（Tier 1；journal；注：IMPa定义性论文；NEB内部研究但发表于ACS Analytical Chemistry（IF~8.0）；奠定ImpaRATOR商品化基础；NEB利益冲突已声明，但方法学独立性可接受；sialic ...）*

[src_434] Noach I, Boraston AB. Structural evidence for a proline-specific glycopeptide recognition domain in an O-glycopeptidase. *Glycobiology*, 2021. DOI: 10.1093/glycob/cwaa102. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8091461/
  *（Tier 1；journal；注：Noach/Boraston（UBC）独立学术研究，无利益冲突；揭示IMPa唾液酸耐受的结构基础，为工程改造提供靶点；2021年Glycobiology（IF~4.7））*

[src_435] Gray MA, Stanczak MA, Mantuano NR 等. Targeted glycan degradation potentiates the anticancer immune response in vivo. *Nature Chemical Biology*, 2020. DOI: 10.1038/s41589-020-0622-x. URL: https://www.nature.com/articles/s41589-020-0622-x
  *（Tier 1；journal；注：Gray/Bertozzi 2020 Nat Chem Biol；确立靶向糖萼降解促肿瘤免疫的体内概念验证，是eStcE治疗化研究的直接前驱；Palleon E-602的学术基础之一）*

⚠️ [src_436] eStcE engineered mucinase — Design for targeted degradation of cancer-associated mucins (DOI: 10.1038/s41587-023-01840-6). *Nature Biotechnology*, 2023. DOI: 10.1038/s41587-023-01840-6. URL: https://www.nature.com/articles/s41587-023-01840-6
  *（Tier 1；journal；注：Nature Biotechnology 2023；eStcE黏蛋白选择性蛋白酶设计，Bertozzi/Stanford；切肽键非糖苷键）*

[src_437] Stanford University - Office of Technology Licensing. Stanford University Technology - Cell-type specific enzymatic degradation of pathological mucins (eStcE fusion construct, WO2023212733). *USPTO / WIPO*, 2023. URL: https://techfinder.stanford.edu/technology/cell-type-specific-enzymatic-degra...
  *（Tier 1；patent；注：Stanford官方技术转让页面；WO2023212733专利核心权利要求针对'融合构型'（eStcE+靶向纳米抗体），eStcE酶本体的单独使用和非HER2靶向构型是否被覆盖需进一步检索full c...）*

[src_438] Palleon Pharmaceuticals. Palleon Pharmaceuticals E-602 (HLX79) Phase 1/2 GLIMMER-01 + Phase 2 Glomerulonephritis Trial. *ClinicalTrials.gov + Palleon Press Releases*, 2022. URL: https://palleonpharma.com/press-releases/palleon-pharmaceuticals-announces-fi...
  *（Tier 1；clinical_trial；注：Palleon E-602是Bertozzi实验室糖萼编辑疗法进入临床的第一个分子（唾液酸酶，非mucinase），但已证明微生物来源工程糖苷酶的人体注射安全性概念；对eStcE治疗化路径有重要参考意...）*

[src_439] Bertozzi CR group, et al.. The protease cathepsin K can debulk the cancer glycocalyx. *Journal of Biological Chemistry (PubMed ID: 41581870)*, 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41581870/
  *（Tier 1；journal；注：2026年JBC；提示治疗化mucinase正向人源化方向演进，缓解细菌来源免疫原性担忧；与eStcE构成技术竞争路径；是判断'治疗化赛道仍早期'的最新数据点）*

⚠️ [src_440] MELiORA ultra-high-throughput droplet screening platform for O-glycopeptidase engineering (Withers/UBC). *Nature Methods / Preprint*, 2024.
  *（Tier 1；journal；注：UBC Withers组MELiORA超高通量液滴筛选平台；已申请UBC专利，用于O-糖肽酶工程化）*

[src_441] Wardman JF, Withers SG. Carbohydrate-active enzyme (CAZyme) discovery and engineering via (Ultra)high-throughput screening. *RSC Chemical Biology*, 2024. DOI: 10.1039/D4CB00024B. URL: https://pubs.rsc.org/en/content/articlehtml/2024/cb/d4cb00024b
  *（Tier 2；review；注：Wardman/Withers 2024 RSC Chem Biol综述；MELiORA平台扩展应用综述；是MELiORA成为CAZyme工程标准方法的佐证文献）*

[src_442] Wardman JF, Withers SG, et al.. Reshaping of a Glycoside Hydrolase Active Site through Expression-Compensated Droplet-Based Microfluidic Screening Provides Useful Tools for Glycomics. *ACS Central Science*, 2025. DOI: 10.1021/acscentsci.5c01227. URL: https://pubs.acs.org/doi/full/10.1021/acscentsci.5c01227
  *（Tier 1；journal；注：Wardman/Withers 2025 ACS Central Science；对Q868G骨架进行液滴微流控定向进化的最新成果；证明单点突变可进一步工程化；是双路线IP布局中路线一的关键科学支撑；...）*

[src_443] Abramson J, et al., DeepMind. AlphaFold3 — Accurate Structure Prediction of Biomolecular Interactions (Nature 2024) and AI-Driven De Novo Protein Design in Enzyme Engineering. *Nature (AlphaFold3) + Biology MDPI review*, 2024. DOI: 10.1038/s41586-024-07487-w. URL: https://www.nature.com/articles/s41586-024-07487-w
  *（Tier 2；review；注：AlphaFold3 Nature 2024原文；结合MDPIreview（Biology 2025，14:1268）对AI蛋白设计在酶工程中应用的综述；AF3是工程酶赛道加速的关键工具；降低理性设计...）*

⚠️ [src_444] Diagnostic biomarkers for IgA nephropathy — galactose-deficient IgA1 (Gd-IgA1) ELISA assay development. *Clinical Chemistry / Journal of Nephrology*, 2023.
  *（Tier 2；journal；注：Gd-IgA1 ELISA诊断测定方法开发；O-糖苷酶在IgAN诊断工作流中的应用）*

[src_445] Teak IP Services, USPTO. PCT Filing Costs and Fees: Complete Breakdown — Teak IP Services / USPTO PCT Fees in USD. *USPTO Official + Teak IP Services*, 2024. URL: https://www.uspto.gov/patents/basics/international-protection/patent-cooperat...
  *（Tier 2；legal_reference；注：PCT费率参考；USPTO官方费率为基准，Teak IP提供完整成本分解；用于第12章预算支撑；利益冲突注意但数量级可信）*

[src_448] Ministry of Finance of China, Ministry of Industry and Information Technology. China Government Procurement Domestic Product Standards — Ministry of Finance/MIIT Notice (effective 2026-01-01). *www.gov.cn (Official China Government Portal)*, 2025. URL: https://english.www.gov.cn/news/202512/19/content_WS69454fa9c6d00ca5f9a0834b....
  *（Tier 1；regulatory；注：2025年12月19日中国财政部+工信部联合发布，2026年1月1日起国产品在政府采购中享有20%评价价格优惠；医疗器械以NMPA国产注册证为'国产'认定依据；是支持供应链轴政策东风的Tier 1监管...）*

[src_447] DelveInsight Business Research. IgA Nephropathy Epidemiology and Market Forecast 2034 — China & 7MM. *DelveInsight*, 2024. URL: https://www.delveinsight.com/report-store/iga-nephropathy-epidemiology-forecast
  *（Tier 2；market_report；注：DelveInsight为Tier 2医疗市场报告，2024年数据；7MM+中国IgAN患者约190万例（2022年）；中国实际患者规模需考虑活检率不足因素，为中国IgAN市场规模的主要公开引用来源）*

[src_446] Zhang et al.. Prevalence and trend of biopsy-proven IgA nephropathy in China: a systematic review. *Journal of Nephrology (Springer)*, 2025. DOI: 10.1007/s40620-025-02265-3. URL: https://pubmed.ncbi.nlm.nih.gov/40138167/
  *（Tier 1；journal；注：2025年发表的中国IgAN最全面系统综述，覆盖34个省市143,176例原发性肾小球疾病活检数据；IgAN占39.73%，是中国最常见原发性肾小球疾病。Italian Society of Neph...）*

[src_451] Everest Medicines (HKEX: 1952.HK). Everest Medicines: NMPA Full Approval of NEFECON for IgA Nephropathy (May 2025). *ACN Newswire / Everest Medicines IR*, 2025. URL: https://www.acnnewswire.com/press-release/english/99552/everest-medicines-ann...
  *（Tier 1；press_release；注：NEFECON获NMPA全批准，扩大至不限蛋白尿水平的成人IgAN患者；中国每年新确诊IgAN逾10万例；已纳入31省市NRDL；印证IgAN诊疗市场快速标准化，对诊断试剂需求产生正向拉动）*

[src_449] Kidney Disease: Improving Global Outcomes (KDIGO) IgAN Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of IgA Nephropathy and IgA Vasculitis. *Kidney International (Supplement)*, 2025. DOI: 10.1016/j.kint.2025.xx. URL: https://kdigo.org/wp-content/uploads/2024/08/KDIGO-2025-IgAN-IgAV-Guideline.pdf
  *（Tier 1；clinical_guideline；注：KDIGO 2025 IgAN/IgAV临床实践指南；明确'目前无经过验证的血清或尿液诊断标志物'；肾活检仍是诊断金标准；东亚裔最高发病率；全球最权威IgAN管理指南，Tier 1监管/临床文献）*

[src_452] Renfrow MB, Novak J, et al.. Analysis of O-glycoforms of the IgA1 hinge region by sequential deglycosylation. *Scientific Reports (Nature Publishing Group)*, 2020. DOI: 10.1038/s41598-020-57510-z. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC6971281/
  *（Tier 1；journal；注：Renfrow/Novak 2020 Sci Rep；确立顺序脱糖（神经氨酸酶→O-糖苷酶）是IgA1铰链区Gd-O-糖型定量分析的标准工作流；EngEF在此工作流中优于SpGH101（残余二糖0.4...）*

[src_450] Cincinnati Children's Hospital Medical Center. Gd-IgA1 Biomarker Screening Service — Cincinnati Children's Hospital Nephrology Clinical Laboratory. *Cincinnati Children's Hospital (CLIA/CAP certified clinical laboratory)*, 2025. URL: https://www.cincinnatichildrens.org/-/media/Cincinnati-Childrens/Home/clinica...
  *（Tier 2；clinical_lab；注：Cincinnati Children's于2025年推出临床Gd-IgA1检测服务，AUC=0.950；CLIA/CAP/GCLP认证；是当前最高规格临床Gd-IgA1实验室检测的性能标杆；印证高特...）*

---

*统计：共 121 条引用，其中 98 条来自 sources.jsonl 完整记录，23 条根据正文上下文推断（⚠️），0 条完全缺失。*

*生成时间：2026-04-21 | 生成工具：dr-reporter*